ArticleBMC cancer2023

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.

Xuefeng Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.